IE66335B1 - Compounds having antiprogestational and antiestrogenic activities for the treatment of hormone-dependent tumors - Google Patents

Compounds having antiprogestational and antiestrogenic activities for the treatment of hormone-dependent tumors

Info

Publication number
IE66335B1
IE66335B1 IE295488A IE295488A IE66335B1 IE 66335 B1 IE66335 B1 IE 66335B1 IE 295488 A IE295488 A IE 295488A IE 295488 A IE295488 A IE 295488A IE 66335 B1 IE66335 B1 IE 66335B1
Authority
IE
Ireland
Prior art keywords
dosage unit
phenyl
tumours
hydroxy
treatment
Prior art date
Application number
IE295488A
Other languages
English (en)
Other versions
IE882954L (en
Inventor
Martin Dr Schneider
Walter Dr Elger
Sybille Dr Beier
Beate Kosub
Krzysztof Dr Chwalisz
Syed Hamiduddin Dr Hasan
Marianne Faehnrich
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IE882954L publication Critical patent/IE882954L/xx
Publication of IE66335B1 publication Critical patent/IE66335B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IE295488A 1987-10-01 1988-09-30 Compounds having antiprogestational and antiestrogenic activities for the treatment of hormone-dependent tumors IE66335B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873733478 DE3733478A1 (de) 1987-10-01 1987-10-01 Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore

Publications (2)

Publication Number Publication Date
IE882954L IE882954L (en) 1989-04-01
IE66335B1 true IE66335B1 (en) 1995-12-27

Family

ID=6337559

Family Applications (2)

Application Number Title Priority Date Filing Date
IE295488A IE66335B1 (en) 1987-10-01 1988-09-30 Compounds having antiprogestational and antiestrogenic activities for the treatment of hormone-dependent tumors
IE295388A IE65165B1 (en) 1987-10-01 1988-09-30 Compounds having antiprogestational and anti-estrogen activities

Family Applications After (1)

Application Number Title Priority Date Filing Date
IE295388A IE65165B1 (en) 1987-10-01 1988-09-30 Compounds having antiprogestational and anti-estrogen activities

Country Status (14)

Country Link
US (2) US4888331A (cg-RX-API-DMAC7.html)
EP (1) EP0310541B1 (cg-RX-API-DMAC7.html)
JP (2) JP2656958B2 (cg-RX-API-DMAC7.html)
AT (2) ATE83149T1 (cg-RX-API-DMAC7.html)
AU (2) AU616208B2 (cg-RX-API-DMAC7.html)
CA (2) CA1329126C (cg-RX-API-DMAC7.html)
DE (3) DE3733478A1 (cg-RX-API-DMAC7.html)
DK (2) DK550188A (cg-RX-API-DMAC7.html)
ES (2) ES2053795T3 (cg-RX-API-DMAC7.html)
GR (1) GR3007225T3 (cg-RX-API-DMAC7.html)
IE (2) IE66335B1 (cg-RX-API-DMAC7.html)
IL (2) IL87885A (cg-RX-API-DMAC7.html)
PH (1) PH26774A (cg-RX-API-DMAC7.html)
ZA (2) ZA887379B (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
DE4329344A1 (de) * 1993-08-27 1995-03-02 Schering Ag Progesteronantagonistisch- und antiöstrogen wirksame Verbindungen für die Behandlung des Leiomyomata uteri
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
AU4980100A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Compositions containing benzimidazolones and progestogens
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) * 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6399593B1 (en) * 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
EP1173210B1 (en) * 1999-05-04 2004-09-15 Wyeth Contraceptive compositions containing antiprogestinic and progestinic
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
DE60021720T2 (de) 1999-05-04 2006-06-01 Strakan International Ltd. Androgen glykoside und die androgenische aktivität davon
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2004510994A (ja) * 2000-10-06 2004-04-08 バイオメディシンズ，インコーポレイティド エストロゲン−感受性疾病の処理のための組み合わせ治療
AU1824302A (en) * 2000-10-18 2002-04-29 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
US6599921B2 (en) 2001-02-22 2003-07-29 Nanodesign, Inc. Non-steroidal estrogen receptor ligands
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
AU2004218474A1 (en) * 2003-02-28 2004-09-16 Dekk-Tec, Inc. Resonance modulator for diagnosis and therapy
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
JP2008515811A (ja) * 2004-10-04 2008-05-15 ウェイン ステイト ユニヴァーシティ 子宮外妊娠の治療のためのアロマターゼ阻害薬の使用方法
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
US7694688B2 (en) 2007-01-05 2010-04-13 Applied Materials, Inc. Wet clean system design
WO2009075838A2 (en) * 2007-12-10 2009-06-18 Meditrina Pharmaceuticals, Inc. Treatment of menorrhagia with aromatase inhibitor
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
DE3337450A1 (de) * 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
ATE75947T1 (de) * 1984-08-02 1992-05-15 Labrie Fernand Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
US4732904A (en) * 1984-12-24 1988-03-22 Morgan Lee R Antiestrogenic hydrazones
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
FR2598083B1 (fr) * 1986-05-05 1989-12-29 Theramex Laboratoire Nouvelles compositions pharmaceutiques a action antiprogesteronique et leur procede d'obtention
DE3633244A1 (de) * 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese

Also Published As

Publication number Publication date
AU616208B2 (en) 1991-10-24
JPH01106822A (ja) 1989-04-24
US5733902A (en) 1998-03-31
IL87885A0 (en) 1989-03-31
CA1329126C (en) 1994-05-03
DK550088A (da) 1989-04-02
IE65165B1 (en) 1995-10-04
US4888331A (en) 1989-12-19
AU2332288A (en) 1989-06-08
PH26774A (en) 1992-09-28
IE882954L (en) 1989-04-01
AU624082B2 (en) 1992-06-04
DK550188A (da) 1989-04-02
AU2332188A (en) 1989-04-20
CA1330039C (en) 1994-06-07
GR3007225T3 (cg-RX-API-DMAC7.html) 1993-07-30
DE3733478A1 (de) 1989-04-13
ZA887379B (en) 1989-05-30
DK550188D0 (da) 1988-09-30
IL87885A (en) 1993-06-10
ES2055745T3 (es) 1994-09-01
IL87886A0 (en) 1989-03-31
DE3850026D1 (de) 1995-07-06
ATE106730T1 (de) 1994-06-15
JP2620333B2 (ja) 1997-06-11
DK550088D0 (da) 1988-09-30
DE3876582D1 (de) 1993-01-21
EP0310541B1 (de) 1992-12-09
IL87886A (en) 1993-06-10
ZA887378B (en) 1989-05-30
EP0310541A1 (de) 1989-04-05
ES2053795T3 (es) 1994-08-01
JP2656958B2 (ja) 1997-09-24
ATE83149T1 (de) 1992-12-15
JPH01106823A (ja) 1989-04-24
IE882953L (en) 1989-04-01

Similar Documents

Publication Publication Date Title
IE66335B1 (en) Compounds having antiprogestational and antiestrogenic activities for the treatment of hormone-dependent tumors
Ruan et al. The pharmacology of dienogest
Sitruk-Ware Progestogens in hormonal replacement therapy: new molecules, risks, and benefits
Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Stanczyk et al. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations
CA2205897A1 (en) Compositions and methods for contraception and for treatment of benign gynecological disorders
CN102014923A (zh) 用于治疗子宫内膜异位症、子宫肌瘤、痛经、乳腺癌的孕酮拮抗剂，例如cdb-4124
SK10497A3 (en) Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
SK78997A3 (en) Compounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception
Druckmann Profile of the progesterone derivative chlormadinone acetate—pharmocodynamic properties and therapeutic applications
EP0310542B1 (de) Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
US20020156059A1 (en) Pharmaceutical combination preparations that contain aromatase inhibitors and substances with estrogenic action as well as their use
Sitruk-Ware Hormone therapy and the cardiovascular system: the critical role of progestins
CA2248841C (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
WO1995005828A1 (de) PROGESTERONANTAGONISTISCH- UND ANTIÖSTROGEN WIRKSAME VERBINDUNGEN FÜR DIE BEHANDLUNG DES $i(LEIOMYOMATA UTERI)
EP1605924B1 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
Simoncini et al. Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels
Snyder et al. Effect of epostane, ZK 98299, and ZK 98734 on the interruption of pregnancy in the rat
CZ293771B6 (cs) Použití steroidních antagonistů estrogenových receptorů pro výrobu léčiv
US7629334B1 (en) Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
Sitruk-Ware Progestins and the cardiovascular system
Greenblatt Is there a place for androgens in gynecological disorders?
Siseles et al. Hormone replacement therapy and lipid profile: effects of
CA2067173A1 (en) Use of antigestagens for the production of pharmaceutical agents

Legal Events

Date Code Title Description
MM4A Patent lapsed